Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Trial of RG1-VLP Vaccine for HPV-Associated Cancer Prevention
NCT05985681Phase 1Recruiting
- Sponsor
- National Cancer Institute
- Start
- Jan 2026
- Primary completion
- Feb 2028
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HPV16 RG1 VLP in human papillomavirus-related carcinoma, sponsored by National Cancer Institute. Primary endpoint: Incidence of adverse events. Started Jan 2026; status: recruiting.
02
Drugs
HPV16 RG1 VLP
03
Conditions
human papillomavirus-related carcinoma
Beyond the preview
Go deeper on NCT05985681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05985681.